Vir Biotechnology Q3 2024 Adj EPS $(1.56) Misses $(1.05) Estimate, Sales $2.40M Miss $5.51M Estimate
Vir Biotechnology Q3 2024 Adj EPS $(1.56) Misses $(1.05) Estimate, Sales $2.40M Miss $5.51M Estimate
vir生物科技2024年第三季度調整後每股收益爲$(1.56)，低於$(1.05)的預估，銷售額爲$240萬，低於預期的$551萬
Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.05) by 48.57 percent. The company reported quarterly sales of $2.40 million which missed the analyst consensus estimate of $5.51 million by 56.45 percent. This is a 9.06 percent decrease over sales of $2.64 million the same period last year.
vir biotechnology(納斯達克:VIR)報告每股虧損$(1.56)，比分析師共識預期$(1.05)低了48.57%。 該公司報告季度銷售額爲$240萬，比分析師共識預期$551萬低了56.45%。 這是相比去年同期$264萬銷售額下降了9.06%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間